SCHEMBL17830739

SCHEMBL17830739

O=C(Cn1c(=O)oc2cc(Cl)ccc21)OCc1cncs1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
HTT P42858 2/20 0.46
ALDH1A1 P00352 3/20 0.45
USP2 O75604 1/20 0.45
MAPT P10636 3/20 0.44
TP53 P04637 2/20 0.44
GRM5 P41594 1/20 0.44
KMT2A Q03164 1/20 0.44
POLB P06746 2/20 0.43
IDO1 P14902 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
CYP3A4 P08684 1/20 0.42
HPGD P15428 1/20 0.42
HSD17B10 Q99714 1/20 0.42
PIK3CB P42338 1/20 0.42
ALPG P10696 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17830732 0.82 USP2 (0.47) LMNAALDH1A1USP2MAPTTP53
SCHEMBL17830724 0.81 IDO1 (0.51) LMNAALDH1A1USP2MAPTTP53
SCHEMBL17830733 0.80 MAPT (0.46) LMNAALDH1A1USP2MAPTTP53
SCHEMBL17830738 0.80 USP2 (0.47) LMNAALDH1A1USP2MAPTTP53
SCHEMBL17830715 0.79 PIK3CB (0.54) NPC1ALDH1A1USP2MAPTTP53
SCHEMBL17830725 0.78 POLB (0.52) LMNAALDH1A1USP2MAPTTP53
SCHEMBL17830737 0.78 ALDH1A1 (0.46) LMNAALDH1A1USP2MAPTTP53
SCHEMBL17830726 0.78 IDO1 (0.55) LMNAALDH1A1USP2MAPTTP53
SCHEMBL17830722 0.78 RECQL (0.55) LMNAALDH1A1USP2MAPTTP53
SCHEMBL17830736 0.77 MIF (0.52) LMNAALDH1A1USP2MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9943506-B2 BCL6 inhibitors as anticancer agents CORNELL UNIVERSITY (US) 2018-04-17 US disclosed
US-9943506-B2 BCL6 inhibitors as anticancer agents CORNELL UNIVERSITY (US) 2018-04-17 US disclosed
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS CORNELL UNIVERSITY 2016-06-16 US disclosed
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS CORNELL UNIVERSITY 2016-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS BCL6, BCL6B, BAZ2A LMNA 3890/4885NPC1 1880/4885RAB9A 3329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.